Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-associated antigen delivery via recombinant adenovirus serotype 5 vector with deleted early region genes (Ad5-TAA)
- Target
- Ad5-TAA
- Molecular classification
- Viral vector, Gene delivery system
01
Overview
Recombinant adenovirus serotype 5 (Ad5) vector with deleted early region genes (E1 and/or E3) used to deliver tumor-associated antigens (TAAs). This approach aims to stimulate an immune response against cancer cells by presenting these antigens and thereby inducing anti-tumor immunity.
- Other names
- rAd5-TAAReplication-defective Ad5 vector expressing TAAE1/E3 deleted Ad5 vector for cancer immunotherapy
02
Mechanism of action
The Ad5 vector infects cells and expresses tumor-associated antigens, leading to antigen presentation and activation of cytotoxic T-cells, thereby inducing anti-tumor immunity.
03
Biological functions
Tumor antigen deliveryInduction of anti-tumor immunityGene therapy
04
Disease associations
Cancer
05
Safety considerations
Pre-existing immunity to Ad5Off-target effectsInflammatory responsesInsertional mutagenesis (rare)
06
Interacting drugs
Checkpoint inhibitors (e.g., Pembrolizumab, Nivolumab)
1 more in the full profile.
07
Biomarkers
TAA expression levels in tumorPre-existing anti-Ad5 antibody titersT-cell response to TAAImmune cell infiltration in tumor microenvironment
Beyond the preview
Go deeper on Tumor-associated antigen delivery via recombinant adenovirus serotype 5 vector with deleted early region genes (Ad5-TAA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-associated antigen delivery via recombinant adenovirus serotype 5 vector with deleted early region genes (Ad5-TAA).